���景与受体作用机制 — Background and Details

By Editorial Desk · published 2026-05-09 · last reviewed 2026-06-16 · News

pentapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-06-16. Numbers and descriptions here follow the published literature rather than marketing material.

背景与受体作用机制

现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。

Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

Background and Structural Identity

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.

Ipamorelin at a glance

Receptor Mechanism and Secretagogue Action

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

Related pages on this site

• Adaptive report
• Automated toolkit
• Portable collection
• Connected report
• Quality update
• Professional toolkit
• Automated index
• Smart comparison

背景与分子特征

在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。

从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。

Ipamorelin Background and Mechanism

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.

Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.

Background and Receptor Selectivity

The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.

Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.

Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.

Supporting material

By doing tandem mass spectrometry in time, the separation is accomplished with ions trapped in the same place, with multiple separation steps taking place over time. A quadrupole ion trap or Fourier transform ion cyclotron resonance instrument can be used for such an analysis. Trapping instruments can perform multiple steps of analysis, which is sometimes referred to as MSn (MS to the n). Often the number of steps, n, is not indicated, but occasionally the value is specified; for example MS3 indicates three stages of separation. Tandem in time MS instruments do not use the modes described next, but typically collect all of the information from a precursor ion scan and a parent ion scan of the entire spectrum. Each instrumental configuration utilizes a unique mode of mass identification.

Liposomes, for instance, are small vesicles that can carry drugs and be modified to circulate longer or home in on specific brain regions. Dendrimers, with their tree-like structure, can hold multiple drug molecules and targeting agents at once. Polymeric nanoparticles, made from biodegradable materials like polylactic acid (PLA) or polylactic-co-glycolic acid (PLGA), can be engineered to release drugs over time in a controlled way. Solid lipid nanoparticles offer another alternative, combining biocompatibility with the ability to cross barriers more efficiently. Altogether, these advances are paving the way for more effective and precise treatments for a range of neurological disorders. Nanotechnology helps to transfer medicine to specific places in the body. Drug delivery in new forms with the assistance of minute particles, like liposomes or polymeric micelles. These particles support the drugs by preventing disintegration and enhancing functionality (Islam et al., 2025). An example would be, they can distribute cancer drugs to the tumors, which reduce the side effects. Researchers also come up with particles, which release drugs when going through certain conditions like heat or light. Despite the nature of this technology, it remains expensive and needs further safety studies. In the near future researchers say there will be a more advanced strategies of treatment such as the use nanomedicine and technology like artificial intelligence (Islam et al., 2025).

== See also == National Glycohemoglobin Standardization Program (NGSP) Good Laboratory Practice (GLP) Institute for Reference Materials and Measurements (IRMM) International Laboratory Accreditation Cooperation ISO 15189 Joint Committee for Traceability in Laboratory Medicine National Institute of Standards and Technology (NIST) Reference values

=== Deconvolution of libraries cleaved from the solid support === If the synthesized molecules of a combinatorial library are cleaved from the solid support, a soluble mixture forms. In such solution, millions of different compounds may be found. When this synthetic method was developed, it first seemed impossible to identify the molecules, and to find molecules with useful properties. Strategies for identification of the useful components have been developed, however, to solve this problem. All these strategies are based on synthesis and testing of partial libraries. An early iterative strategy was devised by Furka in 1982. The method was later independently published by Erb et al. under the name "Recursive deconvolution"

Sources: en.wikipedia.org

Supporting material

Mirtazapine, sold under the brand name Remeron among others, is an atypical tetracyclic antidepressant, and as such is used primarily to treat depression. Its effects may take up to four weeks but can also manifest as early as one to two weeks. It is often used in cases of depression complicated by anxiety or insomnia. The effectiveness of mirtazapine is comparable to other commonly prescribed antidepressants. It is taken by mouth. Common side effects include sleepiness, dizziness, increased appetite, and weight gain. Serious side effects may include mania, low white blood cell count, and increased suicide among children. Withdrawal symptoms may occur when stopping. It is not recommended together with a monoamine oxidase inhibitor, although evidence supporting the danger of this combination has been challenged. It is unclear if use during pregnancy is safe. How it works is not clear, but it may involve blocking certain adrenergic and serotonin receptors. Chemically, it is a tetracyclic antidepressant, and is closely related to mianserin. It also has strong antihistaminergic effects. Mirtazapine came into medical use in the United States in 1996. The patent expired in 2004, and generic versions are available. In 2023, it was the 99th most commonly prescribed medication in the United States, with more than 6 million prescriptions.

Reform UK removes Ian Cooper, leader of Staffordshire County Council, from the party following an investigation into online racist comments. 6 December – It is announced that transgender women will not be allowed to take part in the main event of the 2026 Labour Women's Conference. Former Conservative minister and peer Malcolm Offord defects to Reform UK, and says he will stand down from the House of Lords to campaign in the 2026 Scottish Parliament election. 7 December – Prime Minister Keir Starmer says that Angela Rayner will return to the cabinet, describing her as "hugely talented". 8 December – Essex Police are investigating allegations made by a former Reform UK councillor that the party overspent while campaigning in the Clacton constituency during the 2024 general election. Reform UK selects Addy Mo Asaduzzaman, a Bangladeshi with indefinite leave to remain in the UK, to stand in Central Southsea at local elections in May 2026. The announcement leads to criticism of the party. 9 December – Home Secretary Shabana Mahmood announces that former Children's Commissioner Baroness Anne Longfield will lead the inquiry into grooming gangs. Thirteen Labour MPs back a Liberal Democrat bill requiring the government to begin negotiations on joining a bespoke customs union with the EU, leading to a tied vote of 100–100. In her capacity as holder of the deciding vote Deputy Speaker Caroline Noakes gives her backing to the bill, allowing for it to have further debate. Ian Cooper resigns as leader of Staffordshire County Council after he was expelled by Reform UK.

Photodynamic/photothermal combination therapy involves the usage of a chemical compound or nanomaterial that, when irradiated at a certain wavelength, converts light energy into reactive oxygen species (ROS) and heat. This has shown to be highly effective in the treatment of skin infections, showing increased wound healing rates and a lower impact on human cell viability than photodynamic (PD) or photothermal (PT) therapies. The compounds involved often employ additional mechanisms of action or side effect reduction mechanisms, further increasing their efficacy. Phototherapies are minimally invasive, with the primary toxicity issues surrounding phototoxicity and the nonspecific ROS and heat mechanisms of action affecting healthy human cells (albeit in lower amounts than the target cells). In skin wound infections, multiple phototherapeutic approaches have observed increased rates of wound closure over nontreated controls. This is typically due to an upregulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF). Phototherapies are also active against both gram-positive and gram-negative bacteria, with photodynamic therapy having some exceptions. To apply this technique, a photosensitizer is localized to the wound or tumor site, either topically or intravenously. Once localized, the target area is exposed to a laser of a selected wavelength and intensity for a predetermined irradiation time.

John Lilley states, "...neutron-induced fission generates extra neutrons which can induce further fissions in the next generation and so on in a chain reaction. The chain reaction is characterized by the neutron multiplication factor k, which is defined as the ratio of the number of neutrons in one generation to the number in the preceding generation. If, in a reactor, k is less than unity, the reactor is subcritical, the number of neutrons decreases and the chain reaction dies out. If k > 1, the reactor is supercritical and the chain reaction diverges. This is the situation in a fission bomb where growth is at an explosive rate. If k is exactly unity, the reactions proceed at a steady rate and the reactor is said to be critical. It is possible to achieve criticality in a reactor using natural uranium as fuel, provided that the neutrons have been efficiently moderated to thermal energies." Moderators include light water, heavy water, and graphite. According to John C. Lee, "For all nuclear reactors in operation and those under development, the nuclear fuel cycle is based on one of three fissile materials, 235U, 233U, and 239Pu, and the associated isotopic chains. For the current generation of LWRs, the enriched U contains 2.5~4.5 wt% of 235U, which is fabricated into UO2 fuel rods and loaded into fuel assemblies." Lee states, "One important comparison for the three major fissile nuclides, 235U, 233U, and 239Pu, is their breeding potential.

HLA-G histocompatibility antigen, class I, G, also known as human leukocyte antigen G (HLA-G), is a protein that in humans is encoded by the HLA-G gene. HLA-G belongs to the HLA nonclassical class I heavy chain paralogues. Classical HLA I proteins are found on all nucleated cells and express peptides in their peptide binding groove. They can express "self" peptides when the cell is healthy as well as foreign peptides when the cell is infected by a parasite or cancer. HLA-G is a nonclassical protein and serves a different function from classical HLA class I molecules, but it still expresses a nine amino acid peptide in its peptide binding groove. The third and ninth amino acid in the peptide sequence serve as anchor residues, and are thus conserved in all the peptides HLA-G bind to.

Sources: en.wikipedia.org

Frequently asked questions